Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05006885 · ClinicalTrials.gov registry record · Phase 1
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT05006885 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 95 participants.
The verdict
NCT05006885, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
Interventions
- OTHER Placebo
- DRUG ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05006885
The ClinicalTrials.gov registry entry for NCT05006885 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05006885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05006885 about?
NCT05006885 is a clinical study titled "ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)". The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
What is the current status of trial NCT05006885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2021-09-30. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT05006885?
The interventions under investigation include: Placebo (OTHER), ALT-801 (DRUG).
Who is sponsoring clinical trial NCT05006885?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.